Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2024Frontiers in PediatricsOpen Access

Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLara ChavazLCLaurent CimasoniJHJohanna A. Kremer Hovinga

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chavaz et al. (2024) studied this question.

synapsesocial.com/papers/68e5b74bb6db64358754fe6chttps://doi.org/10.3389/fped.2024.1448801
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Redefining outcomes in immune TTP: an international working group consensus report2021 · 229 citations
  2. 2Thrombotic thrombocytopenic purpura2017 · 714 citations
  3. 3Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura2016 · 675 citations
  4. 4ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP2020 · 78 citations
  5. 5Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura2019 · 1,037 citations